RT @jgilleen: PDE4 inhibitor, Roflumilast, for memory deficits in schizophrenia! Our new clinical trial just published in #Psychopharmacolo…
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients | SpringerLink https://t.co/0ubwEqLo7V
RT @jgilleen: PDE4 inhibitor, Roflumilast, for memory deficits in schizophrenia! Our new clinical trial just published in #Psychopharmacolo…
RT @jgilleen: PDE4 inhibitor, Roflumilast, for memory deficits in schizophrenia! Our new clinical trial just published in #Psychopharmacolo…
@ClinicalRsrchMY
RT @jgilleen: PDE4 inhibitor, Roflumilast, for memory deficits in schizophrenia! Our new clinical trial just published in #Psychopharmacolo…
RT @jgilleen: PDE4 inhibitor, Roflumilast, for memory deficits in schizophrenia! Our new clinical trial just published in #Psychopharmacolo…
RT @jgilleen: PDE4 inhibitor, Roflumilast, for memory deficits in schizophrenia! Our new clinical trial just published in #Psychopharmacolo…
RT @jgilleen: PDE4 inhibitor, Roflumilast, for memory deficits in schizophrenia! Our new clinical trial just published in #Psychopharmacolo…
PDE4 inhibitor, Roflumilast, for memory deficits in schizophrenia! Our new clinical trial just published in #Psychopharmacology! https://t.co/0gc3b5jchW @mehta_mitul72 #CognitiveEnhancement #schizophrenia #PDE4 #CIAS